Get started
Author

Isao Fujioka

Observed names: Fujioka, Isao, フジオカ, イサオ
ORCID: 0000-0001-5883-2270
Observed ORCID: 0000-0001-5883-2270
OpenAlex ID: A5002962620
The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort
2020 · Eriko Sato, Noriyoshi Iriyama, et al. · Cancer Medicine · 37
PDF
Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database
2018 · Isao Fujioka, Tomoiku Takaku, et al. · Annals of Hematology · 28
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group
2017 · Noriyoshi Iriyama, Michihide Tokuhira, et al. · Leukemia Research · 20
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
2018 · Michihide Tokuhira, Yuta Kimura, et al. · Medical Oncology · 19
Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score
2017 · Eriko Sato, Noriyoshi Iriyama, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
2018 · Tomonori Nakazato, Noriyoshi Iriyama, et al. · Medical Oncology · 9
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
2018 · Noriyoshi Iriyama, Kei-Ji Sugimoto, et al. · Medical Oncology · 8
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
2022 · Yuriko Nishiyama-Fujita, Tomonori Nakazato, et al. · Annals of Medicine · 7
PDF
Bosutinib-induced late-onset severe liver injury preceded by eosinophilia
2022 · Naoki Watanabe, Tomoiku Takaku, et al. · Annals of Hematology · 3
Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis
2019 · Noriyoshi Iriyama, Michihide Tokuhira, et al. · Hematological Oncology · 3
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis
2019 · Maho Ishikawa, Noriyoshi Iriyama, et al. · Oncology Reports · 2
PDF
[Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
2017 · Yoko Edahiro, Tomoiku Takaku, et al. · PubMed · 2
[Primary pulmonary Hodgkin lymphoma diagnosed by CT-guided percutaneous biopsy].
2015 · Naoki Watanabe, Isao Fujioka, et al. · PubMed · 2
Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma
2025 · Masaki Suzuki, Isao Fujioka, et al. · Frontiers in Medicine · 1
PDF
Author response for "Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis"
2019 · Iriyama, Noriyoshi, Tokuhira, Michihide, et al. · Publons reviews and discussion
Comparison of the Clinical Outcomes of Nilotinib and Dasatinib Therapies in Newly Diagnosed Patients in the Chronic Phase of Chronic Myeloid Leukemia: A Retrospective Analysis
2018 · Noriyoshi Iriyama, Kei-Ji Sugimoto, et al. · Blood
Analysis of cardiovascular risk factors in nilotinib-treated Japanese CML patients
2018 · Isao Fujioka · The Japanese Society of Hematology
Works count: 19
Citation count: 153
H-index: 7
I10-index: 5
Year
Topic
Type